| EXELIXIS INC. DL-,01 |
| USA |
| Gesundheit |
| US30161Q1040 / 936718 |
| EX9 (Frankfurt) / EXEL (NASDAQ) |
| FRA:EX9, ETR:EX9, EX9:GR, NASDAQ:EXEL |
| - |
| https://www.exelixis.com/ |
|
Exelixis Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. Its lead product, CABOMETYX tablets (cabozantinib), treats advanced renal cell ..
>Volltext.. |
| 9908.53 Mio. EUR |
| 9178.2 Mio. EUR |
| 2009.96 Mio. EUR |
| 798.53 Mio. EUR |
| 677.95 Mio. EUR |
| 2.5 EUR |
| 174.06 Mio. EUR |
| 360.47 Mio. EUR |
| 766.05 Mio. EUR |
| 2.61 |
| -5.71% |
| 32.32% |
| - |
| - |
| - |
| - |
| EXELIXIS |
| 05.04.26 |